(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 October 2019 (24.10.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/204193 A1

(51) International Patent Classification:
A61K 9/16 (2006.01) *A61P 7/02* (2006.01)
A61K 31/4545 (2006.01)

(21) International Application Number:
PCT/US2019/027456

(22) International Filing Date:
15 April 2019 (15.04.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/658,175 16 April 2018 (16.04.2018) US

(71) Applicants: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 & Province Line Road, Princeton, NJ 08543-4000 (US). **PFIZER, INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors: **BADAWY, Sherif, Ibrahim, Farag**; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543-4000 (US). **STEVENS, Timothy, D.**; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543-4000 (US). **KUNTZ, Daniel**; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543-4000 (US). **WAYBRANT, Brett**; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543-4000 (US).

(74) Agent: **OKUN, Jason, M.** et al.; Venable LLP, 1290 Avenue of the Americas, New York, NY 10104-3800 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: APIXABAN FORMULATIONS

(57) Abstract: Apixaban pharmaceutical formulation is provided. Also provided is a use of the apixaban formulation in treatment of a thromboembolic disorder.

WO 2019/204193 A1